Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Key facts

Sponsor

Yu jiren

Principal Investigator

Jiren Yu

First Affiliated Hospital of Zhejiang University

Intervention

Toripalimab(drug)

Enrollment

90 enrolled

Eligibility

18-80 years · All sexes

Timeline

2023 – 2029

Study locations (8)

• The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
• The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
• Huzhou Central Hospital, Huzhou, Zhejiang, China
• Lishui Central Hospital, Lishui, Zhejiang, China
• Ningbo First Hospital, Ningbo, Zhejiang, China
• Ningbo Medical Center LiHuiLi Hospital, Ningbo, Zhejiang, China
• Ningbo Second Hospital, Ningbo, Zhejiang, China
• Taizhou Hospital, Taizhou, Zhejiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Constitutional mismatch repair deficiency syndrome

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT07523763
  Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer
  Blokhin's Russian Cancer Research Center
• RECRUITINGNCT07450612
  Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection
  San Raffaele University
• RECRUITINGNANCT06215677
  Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
  Peking Union Medical College Hospital
• ACTIVE NOT RECRUITINGPHASE2NCT02983578
  Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
  M.D. Anderson Cancer Center
• ACTIVE NOT RECRUITINGPHASE1NCT02359565
  Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
  National Cancer Institute (NCI)

See all trials for Constitutional mismatch repair deficiency syndrome →